Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure
- PMID: 17239701
- DOI: 10.1016/j.amjcard.2006.09.003
Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure
Abstract
Interventions involving calcium cycling may represent a promising approach to heart failure (HF) therapy because calcium handling is known to be deranged in human and experimental HF. Istaroxime is a sodium-potassium adenosine triphosphatase (ATPase) inhibitor with the unique property of increasing sarcoplasmic reticulum calcium ATPase (SERCA) isoform 2a (SERCA2a) activity. Because this was demonstrated in normal experimental models, we investigated whether istaroxime is able to improve global cardiac function and stimulate SERCA in failing hearts. In guinea pigs with 3-month aortic banding (AoB), echocardiographic results showed that istaroxime intravenous infusion (0.11 mg/kg per min) significantly increased both indices of contraction and relaxation (fractional shortening, +18+/-3.7%; aortic flow rate, +19+/-2.9%; peak myocardial systolic velocity, +36+/-7%; circumferential fiber shortening, +24+/-4.1%; peak atrial flow velocity, +69+/-8.6%; isovolumic relaxation time, +19+/-6.9%; and peak myocardial early diastolic velocity, +42+/-12%). In left ventricular sarcoplasmic reticulum microsomes from AoB animals, 100 nmol/L istaroxime normalized the depressed (-32%) SERCA2a maximum velocity and increased SERCA activity (+17%). In muscle strips from hearts from patients undergoing cardiac transplantation, istaroxime (0.1-1.0 micromol/L) increased (in a concentration-dependent manner) developed tension, the maximum and minimum first derivative of tension, and absolute velocity of contraction, while stimulating SERCA activity in sarcoplasmic reticulum microsomes at physiologic free calcium concentrations. In conclusion, istaroxime is presently the only available compound that stimulates SERCA2a activity and produces a luso-inotropic effect in HF.
Similar articles
-
Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.Am J Cardiol. 2007 Jan 22;99(2A):41A-46A. doi: 10.1016/j.amjcard.2006.09.005. Epub 2006 Sep 18. Am J Cardiol. 2007. PMID: 17239704
-
Istaroxime: a new luso-inotropic agent for heart failure.Am J Cardiol. 2007 Jan 22;99(2A):33A-40A. doi: 10.1016/j.amjcard.2006.09.004. Epub 2006 Sep 18. Am J Cardiol. 2007. PMID: 17239702
-
Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.Am Heart J. 2009 Jun;157(6):1035-41. doi: 10.1016/j.ahj.2009.03.007. Epub 2009 Apr 23. Am Heart J. 2009. PMID: 19464414 Clinical Trial.
-
Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.Discov Med. 2011 Aug;12(63):141-51. Discov Med. 2011. PMID: 21878191 Review.
-
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?Heart Fail Rev. 2009 Dec;14(4):277-87. doi: 10.1007/s10741-009-9136-z. Epub 2009 Feb 24. Heart Fail Rev. 2009. PMID: 19238540 Review.
Cited by
-
SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.Cardiovasc Res. 2022 Mar 16;118(4):1020-1032. doi: 10.1093/cvr/cvab123. Cardiovasc Res. 2022. PMID: 33792692 Free PMC article.
-
Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease.Pharmacol Rev. 2011 Sep;63(3):700-27. doi: 10.1124/pr.110.003814. Epub 2011 Jul 7. Pharmacol Rev. 2011. PMID: 21737534 Free PMC article. Review.
-
Major contribution of the 3/6/7 class of TRPC channels to myocardial ischemia/reperfusion and cellular hypoxia/reoxygenation injuries.Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4582-E4591. doi: 10.1073/pnas.1621384114. Epub 2017 May 19. Proc Natl Acad Sci U S A. 2017. PMID: 28526717 Free PMC article.
-
SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications.Br J Pharmacol. 2013 Oct;170(3):486-8. doi: 10.1111/bph.12288. Br J Pharmacol. 2013. PMID: 23822610 Free PMC article.
-
MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca²⁺ overload and cell death.J Clin Invest. 2012 Apr;122(4):1222-32. doi: 10.1172/JCI59327. Epub 2012 Mar 19. J Clin Invest. 2012. PMID: 22426211 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous